Boston Biomedical has dosed the first patient in CanStem303C, a new global Phase III study investigating napabucasin in combination with standard of care (FOLFIRI) in patients with previously treated metastatic colorectal carcinoma (mCRC).

Around 1.4 million patients are diagnosed with colorectal cancer every year, making the disease the fourth leading cause of cancer-related deaths annually, with almost 700,000 deaths reported worldwide.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

An estimated 50% of all colorectal cancer patients will experience disease recurrence.

Boston Biomedical chief medical officer, president and CEO and Sumitomo Dainippon Pharma Group global oncology head Chiang J. Li said: “Early clinical data for napabucasin in combination with FOLFIRI in advanced colorectal cancer has demonstrated encouraging anti-tumour activity even in FOLFIRI-pretreated patients, so we are eager to understand more deeply its potential therapeutic benefits in this difficult-to-treat cancer.

"An estimated 50% of all colorectal cancer patients will experience disease recurrence."

“This milestone study is evidence of our commitment to uncover the full potential of cancer stemness pathway inhibition, and develop innovative second-line options for the colorectal cancer patient population.”

See Also:

Patients in this global Phase III study will be randomised in a 1:1 ratio to receive either two daily doses of 240mg napabucasin, an orally administered investigational agent intended to inhibit cancer stemness pathways by targeting STAT3, as well as biweekly FOLFIRI or biweekly FOLFIRI alone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial also enables the addition of bevacizumab per direction by the study investigator.

The study will see enrolment of a total of 1,250 patients.

The primary endpoint of the study is overall survival, while secondary endpoints include progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), safety and quality of life.

Overall survival, PFS, ORR and DCR analyses will be conducted in the general study population, as well as in biomarker-positive patients.